Cargando…
Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial
BACKGROUND: It remains unclear whether patients’ self‐perceptions of symptoms at baseline clinically impact the prognostic relevance, treatment efficacy, or toxicity profiles in metastatic colorectal cancer (mCRC) patients treated with the first‐line cetuximab and standard chemotherapy. METHODS: The...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050093/ https://www.ncbi.nlm.nih.gov/pubmed/31962002 http://dx.doi.org/10.1002/cam4.2826 |
_version_ | 1783502568883748864 |
---|---|
author | Ooki, Akira Morita, Satoshi Iwamoto, Shigeyoshi Hara, Hiroki Tanioka, Hiroaki Satake, Hironaga Kataoka, Masato Kotaka, Masahito Kagawa, Yoshinori Nakamura, Masato Shingai, Tatsushi Ishikawa, Masashi Miyake, Yasuhiro Suto, Takeshi Hashiguchi, Yojiro Yabuno, Taichi Sakamoto, Junichi Tsuji, Akihito Ando, Masahiko Yamaguchi, Kensei |
author_facet | Ooki, Akira Morita, Satoshi Iwamoto, Shigeyoshi Hara, Hiroki Tanioka, Hiroaki Satake, Hironaga Kataoka, Masato Kotaka, Masahito Kagawa, Yoshinori Nakamura, Masato Shingai, Tatsushi Ishikawa, Masashi Miyake, Yasuhiro Suto, Takeshi Hashiguchi, Yojiro Yabuno, Taichi Sakamoto, Junichi Tsuji, Akihito Ando, Masahiko Yamaguchi, Kensei |
author_sort | Ooki, Akira |
collection | PubMed |
description | BACKGROUND: It remains unclear whether patients’ self‐perceptions of symptoms at baseline clinically impact the prognostic relevance, treatment efficacy, or toxicity profiles in metastatic colorectal cancer (mCRC) patients treated with the first‐line cetuximab and standard chemotherapy. METHODS: The data were collected from a prospective trial that assessed the relationships between quality of life (QOL), treatment efficacy, and adverse events (AEs). RESULTS: The analysis of 137 mCRC patients revealed a significant association between the presence of baseline tumor‐related symptoms and a lower overall survival (OS) compared to the absence of symptoms (HR, 2.49; 95% CI, 1.37‐4.62; P = .003). The asymptomatic responders had favorable outcomes compared to the symptomatic nonresponders (2‐year OS rates: 83.6% and 35.9%, respectively), while the symptomatic responders had similar outcomes to the asymptomatic nonresponders. The median postprogression survival differed significantly: 10.2 months for the symptomatic patients and 15.9 months for the asymptomatic patients (HR, 2.29; 95% CI, 1.25‐4.29, P = .008). The objective response rates and patient toxicity profiles were similar irrespective of the severity of baseline symptoms. CONCLUSION: Baseline symptoms were associated with worse OS but not with impaired treatment efficacy or more frequent AEs in mCRC patients treated with cetuximab in addition to chemotherapy. |
format | Online Article Text |
id | pubmed-7050093 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70500932020-03-05 Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial Ooki, Akira Morita, Satoshi Iwamoto, Shigeyoshi Hara, Hiroki Tanioka, Hiroaki Satake, Hironaga Kataoka, Masato Kotaka, Masahito Kagawa, Yoshinori Nakamura, Masato Shingai, Tatsushi Ishikawa, Masashi Miyake, Yasuhiro Suto, Takeshi Hashiguchi, Yojiro Yabuno, Taichi Sakamoto, Junichi Tsuji, Akihito Ando, Masahiko Yamaguchi, Kensei Cancer Med Clinical Cancer Research BACKGROUND: It remains unclear whether patients’ self‐perceptions of symptoms at baseline clinically impact the prognostic relevance, treatment efficacy, or toxicity profiles in metastatic colorectal cancer (mCRC) patients treated with the first‐line cetuximab and standard chemotherapy. METHODS: The data were collected from a prospective trial that assessed the relationships between quality of life (QOL), treatment efficacy, and adverse events (AEs). RESULTS: The analysis of 137 mCRC patients revealed a significant association between the presence of baseline tumor‐related symptoms and a lower overall survival (OS) compared to the absence of symptoms (HR, 2.49; 95% CI, 1.37‐4.62; P = .003). The asymptomatic responders had favorable outcomes compared to the symptomatic nonresponders (2‐year OS rates: 83.6% and 35.9%, respectively), while the symptomatic responders had similar outcomes to the asymptomatic nonresponders. The median postprogression survival differed significantly: 10.2 months for the symptomatic patients and 15.9 months for the asymptomatic patients (HR, 2.29; 95% CI, 1.25‐4.29, P = .008). The objective response rates and patient toxicity profiles were similar irrespective of the severity of baseline symptoms. CONCLUSION: Baseline symptoms were associated with worse OS but not with impaired treatment efficacy or more frequent AEs in mCRC patients treated with cetuximab in addition to chemotherapy. John Wiley and Sons Inc. 2020-01-21 /pmc/articles/PMC7050093/ /pubmed/31962002 http://dx.doi.org/10.1002/cam4.2826 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Ooki, Akira Morita, Satoshi Iwamoto, Shigeyoshi Hara, Hiroki Tanioka, Hiroaki Satake, Hironaga Kataoka, Masato Kotaka, Masahito Kagawa, Yoshinori Nakamura, Masato Shingai, Tatsushi Ishikawa, Masashi Miyake, Yasuhiro Suto, Takeshi Hashiguchi, Yojiro Yabuno, Taichi Sakamoto, Junichi Tsuji, Akihito Ando, Masahiko Yamaguchi, Kensei Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial |
title | Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial |
title_full | Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial |
title_fullStr | Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial |
title_full_unstemmed | Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial |
title_short | Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial |
title_sort | patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of phase ii quack trial |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050093/ https://www.ncbi.nlm.nih.gov/pubmed/31962002 http://dx.doi.org/10.1002/cam4.2826 |
work_keys_str_mv | AT ookiakira patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial AT moritasatoshi patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial AT iwamotoshigeyoshi patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial AT harahiroki patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial AT taniokahiroaki patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial AT satakehironaga patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial AT kataokamasato patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial AT kotakamasahito patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial AT kagawayoshinori patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial AT nakamuramasato patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial AT shingaitatsushi patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial AT ishikawamasashi patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial AT miyakeyasuhiro patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial AT sutotakeshi patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial AT hashiguchiyojiro patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial AT yabunotaichi patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial AT sakamotojunichi patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial AT tsujiakihito patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial AT andomasahiko patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial AT yamaguchikensei patientreportedsymptomburdenasaprognosticfactorintreatmentwithfirstlinecetuximabpluschemotherapyforunresectablemetastaticcolorectalcancerresultsofphaseiiquacktrial |